FRAP Protein Target for Malaria Vaccine and Heme Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies and vaccines are inadequate for effectively treating and preventing malaria caused by Plasmodium parasites, as they fail to target key antigens recognized by the host immune system and do not adequately address the mechanisms of parasite invasion and heme polymerization.
Innovation Solution
The identification and utilization of Fasciclin Related Adhesive Protein (FRAP) as a therapeutic target, which is involved in parasite invasion and heme polymerization, including the development of vaccines and drugs that elicit an immune response or inhibit FRAP activity, and the use of recombinant proteins and antibodies specific to FRAP sequences to prevent infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antimalarials are used, then treatment is provided, but parasite resistance develops and therapy becomes inadequate
Solution Approach 1:
The patent extracts and targets specific essential parasite proteins (FRAP, heme polymerization enzymes) that are critical for parasite survival. By focusing therapeutic intervention on these extracted key targets rather than broad-spectrum approaches, the treatment maintains effectiveness while reducing selective pressure for resistance development.
Solution Approach 2:
The patent employs vaccines and therapeutics that induce immune responses with specific parameters (antibody affinity, T-cell activation levels) tailored to recognize and neutralize parasite antigens. This parameter-specific approach allows precise targeting of parasite functions without promoting broad resistance.
2Reliability
If vaccines are developed to prevent malaria, then immune protection is achieved, but the complex interplay of host-pathogen-environment mechanisms remains difficult to decipher
Solution Approach 1:
The patent segments the complex immune response into discrete components targeting specific parasite antigens (FRAP, circumsporozoite protein, thrombospondin-related anonymous protein). Each vaccine component is designed to elicit a specific immune response, simplifying the understanding and development of protective immunity mechanisms.
Solution Approach 2:
The patent employs attenuated sporozoite vaccines that undergo preliminary X-Ray or gamma radiation treatment to reduce virulence while preserving immunogenicity. This preliminary action allows the vaccine to safely induce protective immunity without causing disease, simplifying the host-pathogen interaction study.
3Reliability
If sporozoite adhesion and liver cell invasion are prevented, then infection onset is blocked, but the specific antigens recognized by the host immune system remain unidentified
Solution Approach 1:
The patent employs immunological studies and antibody responses as feedback mechanisms to identify which parasite antigens are recognized by the host immune system. By analyzing immune responses to vaccine components and natural infection, the specific antigens involved in adhesion and invasion are identified and characterized.
Solution Approach 2:
The patent replaces direct observation of complex immune mechanisms with molecular biology techniques (protein sequencing, antibody binding assays, gene expression analysis) to identify specific antigens. This substitution allows precise identification of molecular targets without needing to directly observe the complex immune recognition process.
4Object-affected harmful factors
If heme polymerization is inhibited, then toxic heme accumulation occurs, but the specific parasite proteins responsible for this process are not fully understood
Solution Approach 1:
The patent uses heme polymerization inhibitors and antibodies as intermediary tools to study the function of parasite proteins involved in heme metabolism. These intermediaries allow researchers to block or modulate the polymerization process and observe the effects, thereby identifying and characterizing the responsible proteins without directly observing the complete metabolic pathway.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
FRAP serves as an effective target for vaccine development and therapeutic intervention, preventing parasite invasion and neutralizing toxic heme, thereby offering a promising approach to combat malaria.
Implementation Method 1
FRAP catalyzes the neutralization of toxic heme into non-toxic hemozoin
Implementation Method 2
The composition elicits an immune response to Plasmodium
Data Source
AI summary
A novel Fasciclin Related Adhesive Protein (FRAP) from Plasmodium and related parasites is provided as a target for therapeutic intervention in diseases caused by the parasites. FRAP has been shown to play a critical role in adhesion to, or invasion into, host cells by the parasite. Furthermore, FRAP catalyzes the neutralization of heme by the parasite, by promoting its polymerization into hemozoin. This invention provides methods and compositions for therapies based on the administration of protein, DNA or cell-based vaccines and/or antibodies based on FRAP, or antigenic epitopes of FRAP, either alone or in combination with other parasite antigens. Methods for the development of compounds that inhibit the catalytic activity of FRAP, and diagnostic and laboratory methods utilizing FRAP are also provided.